A study published on June 15, 2026, in the European Journal of Clinical Nutrition found that sugar-free diets may pose an unexpected risk to cardiovascular health, according to the research team. The findings challenge long-held assumptions about artificial sweeteners, which have been widely promoted as safe alternatives to sugar in weight management and diabetes prevention. The research arrives at a pivotal moment, as global consumption of low-calorie sweeteners has surged—reaching an estimated 1.7 million metric tons annually by 2025, according to market data from Statista—and regulatory scrutiny intensifies following decades of mixed evidence.
Methodology and Key Findings
The study, led by Dr. Anna Hofmann of the University of Vienna’s Department of Nutritional Sciences, represents the largest longitudinal analysis to date on artificial sweeteners and cardiovascular risk. The research team collaborated with the Austrian Heart Foundation and leveraged data from the Vienna Health Study, a five-year prospective cohort study involving 12,000 participants aged 30–75. Of these, 3,200 reported daily consumption of sugar-free products containing erythritol, aspartame, or sucralose, while 4,800 served as non-consumers. The remaining participants consumed sweeteners less than three times per week.
The primary outcome measured was a composite of major adverse cardiovascular events (MACE), including fatal and non-fatal myocardial infarctions, ischemic strokes, and coronary revascularization procedures. Over the study period, participants in the highest quartile of erythritol intake (median 1.8 grams/day, equivalent to ~12 diet sodas or sugar-free desserts) exhibited a 14% higher incidence of MACE compared to non-consumers, with a hazard ratio of 1.14 (95% CI, 1.02–1.28). The association persisted after adjusting for age, sex, BMI, smoking status, hypertension, diabetes, and baseline lipid profiles.
Subgroup analyses revealed the effect was most pronounced in individuals with pre-existing metabolic syndrome (HR 1.32; 95% CI, 1.10–1.58) or type 2 diabetes (HR 1.25; 95% CI, 1.03–1.52). Mechanistically, the study identified erythritol as the primary driver of risk, with plasma erythritol levels ≥10 mg/dL associated with elevated markers of endothelial dysfunction, including reduced nitric oxide bioavailability and increased platelet aggregation. The authors noted that erythritol’s structural similarity to glucose may contribute to unintended metabolic signaling, despite its minimal caloric impact.
Dr. Hofmann emphasized that the findings do not condemn sugar-free diets outright but call for a reassessment of current safety thresholds. “The data suggest that for certain populations—particularly those with cardiovascular risk factors—moderation is key,” she stated in a press release. The study was funded by the Austrian Science Fund (FWF) and the European Research Council, with peer review conducted by an international panel including experts from Harvard T.H. Chan School of Public Health and the University of Oxford.
Regulatory and Industry Context
The study’s publication coincides with ongoing regulatory reviews in both the EU and U.S. In Europe, the European Food Safety Authority (EFSA) has maintained that erythritol’s acceptable daily intake (ADI) of 0–40 mg/kg body weight is “safe based on existing data,” citing a 2022 review that found no adverse effects at doses up to 10 times the current limit. However, the EFSA’s Panel on Dietetic Products, Nutrition, and Allergies (NDA) has acknowledged the new study as “a signal that warrants further investigation,” particularly given erythritol’s growing use in “zero-sugar” products, which now account for 30% of the global low-calorie sweetener market.
A spokesperson for the International Sweeteners Association (ISA) reiterated that the evidence remains “inconclusive” and pointed to a 2025 meta-analysis in JAMA Network Open that found no significant cardiovascular risks associated with aspartame or sucralose. The ISA noted that erythritol, unlike other sweeteners, is naturally occurring in fruits and fermented foods, though the study’s authors clarified that dietary intake from whole foods does not replicate the high, concentrated exposures seen in processed products.
In the U.S., the FDA’s stance remains aligned with its 2023 GRAS (Generally Recognized as Safe) determinations for erythritol, aspartame, and sucralose. However, the agency’s Center for Food Safety and Applied Nutrition (CFSAN) has flagged the study as part of its ongoing Closer to Zero initiative, which aims to reduce dietary factors contributing to chronic disease. An FDA spokesperson stated, “While we do not alter our guidance based on a single study, we are monitoring emerging data and will consider additional research as it becomes available.” The agency has not scheduled a formal re-evaluation of erythritol’s safety but has requested additional toxicity studies from manufacturers.
Broader Scientific Landscape
The findings build on a decade of conflicting research. A 2020 study in Circulation linked sucralose to a 28% increased risk of stroke, while a 2023 randomized trial in The Lancet Diabetes & Endocrinology found no cardiovascular harm from aspartame. The discrepancy underscores the challenges of studying artificial sweeteners, where observational studies often yield mixed results due to confounding factors like baseline health status or concurrent medication use. Dr. David Ludwig, a professor of nutrition at Harvard Medical School, noted that the new study’s strength lies in its large sample size and rigorous adjustment for confounders, though he cautioned that “observational data cannot prove causation.”
The study also aligns with growing concerns about the metabolic mismatch hypothesis, which posits that artificial sweeteners may disrupt glucose metabolism by triggering sweet taste receptors without caloric compensation, leading to compensatory overeating or insulin resistance. A 2024 review in Nature Reviews Endocrinology highlighted erythritol’s unique role in this paradigm, as its rapid absorption and excretion may create “metabolic noise” that confuses regulatory pathways.
Public Health Implications and Policy Shifts
The study has reignited debates about the role of artificial sweeteners in public health, particularly in light of the World Health Organization’s (WHO) 2024 downgrade of its recommendation for non-sugar sweeteners. The WHO now advises that sweeteners “should not be used as a substitute for reducing free sugars intake” and that their use in children and pregnant women should be minimized. The new research could further influence guidelines, especially for high-risk populations.
In Europe, the European Commission’s Directorate-General for Health and Food Safety (DG SANTE) has initiated a formal safety evaluation of erythritol, with a preliminary report expected by early 2027. The process will involve a public consultation and may lead to revised ADI limits or mandatory labeling requirements. Meanwhile, the UK’s Food Standards Agency (FSA) has issued interim advice urging consumers to “limit intake of products high in artificial sweeteners,” particularly for those with diabetes or cardiovascular disease.
Consumer advocacy groups have called for greater transparency. The Center for Science in the Public Interest (CSPI) released a statement urging manufacturers to disclose erythritol content on product labels and fund independent long-term studies. Lena Torres, CSPI’s director of nutrition policy, stated, “This study is a wake-up call. For years, companies have marketed these products as health foods, but the science is catching up to the risks.”
Expert Perspectives and Clinical Context
Health professionals emphasize that the study does not justify panicking about occasional use of sugar-free products. Dr. Michael Chen, a cardiologist at Johns Hopkins University and a member of the American Heart Association’s Nutrition Committee, noted that the observed risks are modest and may be outweighed by benefits for individuals managing obesity or diabetes. “For someone with type 2 diabetes, replacing a sugary soda with a diet version might still be the better choice,” Chen said. “But this study suggests that if you’re drinking multiple diet sodas a day, it’s worth reconsidering.”
Dr. Hofmann’s team also clarified that the study does not apply to stevia or monk fruit sweeteners, which were not included in the analysis. These natural sweeteners have a different metabolic profile and remain under less scrutiny. However, the authors called for standardized testing across all non-nutritive sweeteners to address gaps in the evidence base.
What Comes Next?
Regulatory agencies, manufacturers, and researchers are now at a crossroads. The European Commission’s evaluation will be critical, as it may set a precedent for global safety assessments. In the U.S., the FDA’s next steps could include requesting additional post-market surveillance data from erythritol producers, such as PepsiCo (which uses erythritol in its Zero Sugar beverages) and Coca-Cola (which markets Diet Coke with aspartame). Both companies have stated they will “review the study carefully” but have not committed to reformulating products.
Consumer advocacy groups are pushing for immediate action. The CSPI has filed a petition with the FDA and EFSA requesting a ban on erythritol in products marketed to children, citing concerns about developmental effects on gut microbiota. Meanwhile, the American Diabetes Association (ADA) has formed a task force to review the evidence and update its 2026 nutrition guidelines, with a draft expected in late 2026.
For individuals considering dietary changes, experts advise caution and personalized guidance. “Artificial sweeteners can be part of a balanced diet, but they are not a cure-all,” Dr. Hofmann reiterated. “If you rely on them daily, it’s worth discussing alternatives with a healthcare provider, especially if you have cardiovascular risk factors.”
Practical Next Steps
• Consult a healthcare provider before making significant changes to your diet, particularly if you have diabetes, heart disease, or metabolic syndrome. A registered dietitian or cardiologist can help assess whether sugar-free alternatives are appropriate for your needs.
• Monitor intake: If you consume sugar-free products regularly, be mindful of portion sizes and consider gradually reducing reliance on them.
• Stay informed: Follow updates from regulatory agencies like the EFSA and FDA, as well as reputable sources like the American Journal of Clinical Nutrition or JAMA, for emerging evidence.
• Explore alternatives: Natural sweeteners like stevia or monk fruit may offer a middle ground, though their long-term effects also require further study.
Key Takeaways
• The study suggests a modest but statistically significant link between high erythritol intake and cardiovascular risk, particularly in high-risk groups.
• Regulatory agencies have not changed safety guidelines but are reviewing the evidence.
• The findings do not prove causation and require confirmation through randomized controlled trials.
• For most people, occasional use of sugar-free products is unlikely to pose harm, but daily consumption warrants discussion with a healthcare provider.
Consult your healthcare provider before making significant dietary changes.
Find more reporting in our Health section.
